Reserve Inotropes for Select Cases of Acute or End-Stage Heart Failure

September 2019

Do the IV inotropes dobutamine and milrinone still have a role in treating heart failure with reduced ejection fraction (HFrEF)?

Yes...but only in a small subset of patients.

Both meds increase arrhythmias. And widespread use fell out of favor years ago...due to concerns about increased mortality, especially in patients withOUT low cardiac output and hypotension.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Learn More

Already a subscriber? Log in

Not sold to individuals

Immunology Implement Strategies to Tackle the IVIG Shortage
Hazardous Meds Be Prepared to Answer Questions About Hazardous Meds and USP 800
Pneumonia Don't Automatically Add Empiric Anaerobic Coverage for Aspiration Pneumonia
Surgery Assess Perioperative Infection Risk for Immunosuppressants and Biologics
Heart Failure Reserve Inotropes for Select Cases of Acute or End-Stage Heart Failure
Vaccines Anticipate Changes for the Use of Prevnar 13 in Seniors
Kidney Disease Be Aware of Nuances When Using Phosphate Binders
HIV & AIDS Stop MAC Prophylaxis in Some HIV Patients
Anticholinergics Put the Dementia Link With Anticholinergics in Perspective
Osteoporosis Be Prepared if Your Infusion Center Gives Romosozumab (Evenity) for Osteoporosis

Reserve Inotropes for Select Cases of Acute or End-Stage Heart Failure

Get unlimited access through an Enterprise license

Table of Contents